ReviewFrontiers in immunology2025
The gut-lung axis in severe pneumonia-related lung injury: mechanisms and therapeutic strategies.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Gut-Lung Microbiome Axis in Alveolar Stem Cell Regeneration and Lung Repair.Microorganisms · 2026Review
- The Gut-Lung Microbiome Crosstalk and Pulmonary Disease.Biomolecules · 2026Review
- Translating priority effects and niche engineering into rational microbiome therapeutics across the gut-lung axis.Frontiers in microbiology · 2026Review
- Source-stratified gut-extraintestinal organ crosstalk in sepsis-associated acute gastrointestinal injury and paralytic ileus: the gut as both driver and target.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe pneumonia-related lung injury is a life-threatening condition associated with high morbidity and mortality. Recent advances in research on the gut-lung axis have provided novel insights into its pathophysiology and revealed potential therapeutic targets. Within the conceptual framework of the microorganism-immunity-metabolism network, modulation of the gut microbiota has emerged as a promising strategy for intervention. Therapeutic approaches such as probiotics, prebiotics, synbiotics, and fecal microbiota transplantation aim to enhance microbial diversity and alter metabolite profiles, thereby optimizing immune responses and attenuating systemic and pulmonary inflammation. This review explores the mechanistic underpinnings of the gut-lung axis in the context of severe pneumonia-related lung injury, with a particular focus on microbiota-targeted interventions. Our goal is to provide a theoretical foundation for the clinical application of gut microbiota modulation in the prevention and treatment of severe pneumonia-related lung injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.